The FDA has approved Abraxane
(nanoparticle albumin bound paclitaxel)
for the first-line treatment of locally advanced or metastatic
non-small cell lung cancer, in combination with carboplatin, in
patients who are not candidates for curative surgery or radiation
therapy.
No comments:
Post a Comment